CRINETICS PHARMACEUTICALS INC. - COMMON STOCK

Crinetics Pharmaceuticals Announces January 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

10 Jan 2024 15:33:42 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

03 Jan 2024 07:00:00 By Nasdaq GlobeNewswire

Crinetics Announces Positive Initial Findings from Ongoing Open-Label Phase 2 Study of Paltusotine for the Treatment of Carcinoid Syndrome

18 Dec 2023 15:05:00 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Announces December 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

11 Dec 2023 15:05:00 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals to Participate in Upcoming Investor Conferences

20 Nov 2023 15:05:00 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Announces November 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

10 Nov 2023 16:00:00 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update

07 Nov 2023 15:05:00 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

10 Oct 2023 16:00:00 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals to Participate in the Cantor Global Healthcare Conference 2023

20 Sep 2023 07:00:00 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock

12 Sep 2023 21:26:42 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock

11 Sep 2023 15:01:22 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

11 Sep 2023 05:00:48 By Nasdaq GlobeNewswire

Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-1 Study Evaluating Treatment of Patients with Acromegaly

10 Sep 2023 09:00:04 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

10 Aug 2023 16:34:32 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update

08 Aug 2023 06:00:01 By Nasdaq GlobeNewswire

Crinetics Hosting Key Opinion Leader Webinar to Discuss the Current Treatment Landscape and Unmet Need in Acromegaly

31 Jul 2023 07:01:44 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

10 Jul 2023 15:19:04 By Nasdaq GlobeNewswire

New Data Demonstrating Stable Biochemical and Symptom Levels with Two-Years of Oral Paltusotine Administration Presented at ENDO 2023

21 Jun 2023 06:59:39 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

12 Jun 2023 06:30:09 By Nasdaq GlobeNewswire

Crinetics to Highlight Broad Pipeline at ENDO 2023

09 Jun 2023 06:30:08 By Nasdaq GlobeNewswire